Obinutuzumab in Marginal Zone Lymphoma

Clinical trial NCT03322865 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03322865
Sponsor: Christian Buske
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Marginal Zone Lymphoma

Start date: 2018-11-23
Primary completion: 2027-01-01
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.